Mereo BioPharma Group plc - Sponsored ADR
MREO Healthcare Biotechnology
Mereo BioPharma Group plc - Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $500,000.00, down 95.0% from fiscal 2023. In the quarter to June 2026, EPS grew 52.3% and free cash flow grew 21.0%, each against the same quarter a year earlier.
Follow MREO
Mereo BioPharma Group plc - Sponsored ADR (MREO) P/E ratio
Mereo BioPharma Group plc - Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2025 | 0.0× | — |
| Dec 2023 | 0.0× | — |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACET Adicet Bio, Inc. compare | n/m |
| KLRS Kalaris Therapeutics Inc. compare | n/m |
| LONA LeonaBio, Inc. compare | n/m |
| ELTX Elicio Therapeutics, Inc. compare | n/m |
| HOWL Werewolf Therapeutics, Inc. compare | n/m |
| MREO Mereo BioPharma Group plc - Sponsored ADR | n/m |
| HYPD Hyperion DeFi, Inc. compare | n/m |
| INKT MiNK Therapeutics, Inc. compare | n/m |
| CRBU Caribou Biosciences, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)